NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Cognitive, Neuro & Sleep/DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide)

Nonapeptide first described in the late 1970s as a sleep-promoting factor; human sleep effects have been inconsistent across published studies.

Overview

Delta sleep-inducing peptide (DSIP) is a nonapeptide first described in the late 1970s, following experiments in which a sleep-promoting factor was isolated from the blood of rabbits induced to sleep. Its name reflects early observations that it increased delta (slow-wave) sleep in animal recipients.

Despite decades of research interest, DSIP's role in human sleep regulation remains uncertain, and published human studies have produced inconsistent results. It persists as a commonly listed research peptide with proposed actions beyond sleep.

Mechanism

No clearly defined receptor or signaling pathway for DSIP has been established. Proposed mechanisms have included modulation of central neurotransmitter systems, effects on the hypothalamic-pituitary-adrenal axis, and influences on neuropeptide processing, but the evidence base is old and limited.

Reported effects in animal work include alterations in sleep architecture, stress-hormone patterns, pain sensitivity, and some metabolic parameters; independent replication has been inconsistent.

Dosing

No standard or validated dosing exists. In animal studies the peptide is often given centrally (intracerebroventricularly) or systemically at microgram-scale amounts per animal; early human studies used intravenous administration before sleep.

  • Rodent work frequently uses central or systemic administration at microgram amounts per animal
  • Early human studies gave the peptide intravenously in the evening
  • Protocols vary widely, and none is clinically validated

Expected Effects

  • Increased delta sleep reported in some early animal studies
  • Effects on human sleep were inconsistent across published trials
  • Stress-hormone and metabolic effects reported in animal work remain poorly replicated

Side Effects & Tolerability

No serious adverse effects were reported in the small, older human studies, but modern safety and pharmacokinetic data are lacking.

Storage

Store lyophilized DSIP frozen, desiccated, and protected from light; follow supplier reconstitution guidance and stability windows.

Related peptides

BDNF Mimetic PeptidesGeneric category of peptides promoted as BDNF mimetics; specific products are not identified in the literature.Blood-Brain Barrier Peptide AnalogsCatalog name implying peptides that cross or act at the blood-brain barrier; no specific products are defined in the literature.Central Pain Pathway Modulator AnalogsUmbrella catalog name implying peptides acting on central pain processing; no specific compounds are documented.Cerebrolysin Peptide FractionPharmaceutical preparation of low-molecular-weight peptides derived from porcine brain, approved in some countries for dementia and stroke recovery.CNTF AnalogsCategory of products sold as CNTF-related peptides; CNTF and its clinical analog Axokine are real, but these items are not documented.ConolidineMonoterpene indole alkaloid from Tabernaemontana divaricata studied as a candidate non-opioid analgesic; a small molecule, not a peptide.